Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Alphyn Biologics

Request full access

Develops first-in-class, multi-target therapeutics for atopic dermatitis and other severe and common skin diseases

Annapolis Neck, United StatesFounded 2019Biotech & Life Sciences

About Alphyn Biologics

Alphyn Biologics is a life science company focused on developing a new class of drugs called Multi Target therapies to treat severe and prevalent skin diseases. The company leverages its patent-pending AB 101 platform biomaterial, which contains multiple bioactives, to address complex skin conditions. Alphyn's primary target is Atopic Dermatitis (AD), also known as Eczema, a condition that affects millions globally and is notoriously difficult to treat. The AB 101 platform aims to tackle all aspects of AD, including immune response issues like inflammation and itch, as well as bacterial problems such as infections and MRSA drug-resistant bacteria.

Alphyn Biologics operates in the pharmaceutical and biotechnology market, serving patients with severe skin conditions. The company follows a business model centered on research and development, aiming to bring innovative treatments to market through FDA approval processes. Revenue is generated through the commercialization of its proprietary therapies.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2019
Headquarters
Annapolis Neck, United States
Employees
4
Open positions
None listed
Dealroom signal
57.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Dec 2025 $25M $100M QCA Ventures ↗
EARLY VC✓Equity / VC Mar 2024 $5.2M $21M Undisclosed ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Alphyn Biologics website traffic

Latest recorded traffic for Alphyn Biologics is 740 monthly website visits, down 38.3% over the last three months. Alphyn Biologics's team grew 0% over the past year.

Latest monthly visits740 3-month web change-38.3% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Alphyn Biologics in the Annapolis Neck ecosystem

Live from Dealroom

The Alphyn Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • QCA Ventures
  • Serial Stage Venture Partners
  • Angel Physician Fund
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Alphyn Biologics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Alphyn Biologics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.